Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit

2Firsts Events
Feb.24
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Several vape manufacturers and distributors, including Shenzhen Smoore Technology Co. Ltd., Smoore International Holdings, 3Win Corp., Jupiter Research LLC, Canna Brand Solutions, and Greenlane Holdings Inc., have filed motions seeking dismissal of consumer claims in consolidated antitrust litigation in the U.S. District Court for the Northern District of California.

Key Points

 

  •  Vape manufacturers and distributors seek dismissal of antitrust MDL claims.

 

  •  Defendants argue consumers lack standing in the distribution chain.

 

  •  Plaintiffs allege price-fixing tied to cannabis vape hardware.

 

  •  Motions challenge sufficiency of conspiracy and pricing allegations.

 

  •  Case is pending in the Northern District of California.

 


 

2Firsts, February 24, 2026

 

According to Law360, Vape manufacturers and distributors have moved to dismiss consumer antitrust claims in consolidated multidistrict litigation pending in the U.S. District Court for the Northern District of California.

 

In motions filed Friday, distributor defendants 3Win Corp., Jupiter Research LLC, Canna Brand Solutions and Greenlane Holdings Inc., along with manufacturers Shenzhen Smoore Technology Co. Ltd. and Smoore International Holdings, argued that plaintiffs have failed to establish standing or plausibly allege a price-fixing conspiracy.

 

The litigation concerns closed cannabis oil vaporization systems and related components. Plaintiffs allege that distributor defendants entered into agreements with manufacturer Smoore to create a price floor and restrict the purchase of competing products, resulting in higher prices for cannabis-filled vape products.

 

Defendants contend that they manufacture and distribute empty vape hardware, not cannabis-filled products, and that these constitute distinct markets. They argue that consumers are too far removed in the commercial chain to assert antitrust claims, as they do not directly participate in the relevant hardware markets.

 

The motions further assert that the third amended complaint fails to allege specific pricing practices, including the prices charged by manufacturers to distributors, by distributors to retailers, or the amounts ultimately paid by consumers. Defendants also argue that the complaint does not adequately allege market share or demonstrate that the alleged conduct foreclosed competition across the relevant California market.

 

Additionally, defendants maintain that although plaintiffs have refiled claims under California’s Cartwright Act following dismissal of federal antitrust claims, the relief sought relates to cannabis products that remain federally illegal.

 

The consolidated case, In re: CCell Closed Cannabis Oil Vaporization Systems and Components Products Litigation, includes four consumer actions and one retailer action. The court has not yet issued a decision on the dismissal motions.

 

(Cover Photo: Cover page of a U.S. District Court (N.D. California) filing showing Smoore defendants’ motion to dismiss in the closed cannabis oil vaporizer antitrust class action. Source: U.S. District Court for the Northern District of California public filing (via Law360).)

FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup’s 2026 Consumption Habits survey tracked nicotine pouch use for the first time. The survey found that 11% of U.S. adults reported smoking cigarettes in the past week, 9% reported vaping, and 4% reported using nicotine pouches. Cigarette smoking remained near Gallup’s long-term low, while adult vaping rates stayed relatively stable in recent years.
Market
Aug.25 by 2Firsts Perspectives
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25